Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Trapiella-Martínez Luis, Díaz-López José Bernardino, Caminal-Montero Luis, Tolosa-Vilella Carles, Guillén-Del Castillo Alfredo, Colunga-Argüelles Dolores, Rubio-Rivas Manuel, Iniesta-Arandia Nerea, Castillo-Palma María Jesús, Sáez-Comet Luis, Egurbide-Arberas María Victoria, Ortego-Centeno Norberto, Freire Mayka, Vargas-Hitos Jose Antonio, Ríos-Blanco Juan José, Todolí-Parra Jose Antonio, Rodríguez-Carballeira Mónica, Marín-Ballvé Adela, Chamorro-Fernández Antonio Javier, Pla-Salas Xavier, Madroñero-Vuelta Ana Belén, Ruiz-Muñóz Manuel, Fonollosa-Pla Vicent, Simeón-Aznar Carmen Pilar, RESCLE Investigators, on Behalf of the Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI)
Аннотация
METHODS: The characteristics of very early and early SSc patients were compared. A logistic regression model was used to determine the risk factors of progression.
RESULTS: 1632 patients were included, 36 (2.2%) in the very early subset and 111 (6.8%) in the early subset. There were no differences in sex, age at disease onset, duration of Raynaud's phenomenon, antinuclear antibodies or capillaroscopic findings. Three (8.3%) very early SSc patients evolved to definite SSc, 2 (5.6%) of them meeting the ACR/EULAR 2013 criteria, unlike 31 (28%) early SSc patients, 20 (24%) of them meeting the criteria (p=0.034). Digestive involvement was an independent risk factor of progression (OR 17; 95% CI, 6.1-47.2).
CONCLUSIONS: The classification of early forms of scleroderma identifies patients with different prognostic risk of progression. The evolution to definite SSc is more frequent in early than in very early SSc patients. Digestive involvement is a risk factor of progression. An active assessment of organ damage in preclinical stages allows a correct classification and risk stratification, with implications for monitoring and treatment.